Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This is a 28-week extension to a study of the safety and effectiveness of three doses of
vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose
levels in people with type 2 diabetes who have not been previously treated with drug therapy
to lower their blood sugar. The purpose of the extension study is to gather long-term safety
and efficacy data for vildagliptin in people with type 2 diabetes.